Exagen (XGN) Insider Scott Kahn Buys 37,500 Shares
Scott Kahn purchased 37,500 shares of XGN on June 9, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Scott Kahn bought 37,500 shares of Exagen Inc. ($XGN) on June 9, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $XGN is up 5.6% after 1 week, up 7.2% after 1 month and up 79.1% to date (from the $4.31 close on Jun 9, 2026).
XGN
Exagen Inc.
Key Points
- Scott Kahn bought 37,500 shares of XGN on June 9, 2026, reflecting insider confidence.
- XGN shares traded near $4.45 on Monday, with active institutional involvement.
- Analysts maintain a positive outlook on XGN, with BTIG setting an $8 price target.
Get $XGN trade alerts by text
We text you when insiders, Congress or big funds trade $XGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Exagen Inc. alert may contain errors. Disclosures
Scott Kahn increased his stake in XGN by purchasing 37,500 shares on June 9, 2026. This insider transaction comes amid a period of active institutional trading in the company's stock.
Other Institutional Activity in XGN
Several institutional investors have recently adjusted their positions in XGN. Wexford Capital LP increased its holdings by 326,077 shares, bringing its total to 792,855 shares valued at about $2,378,565, marking a 69.9% increase. Acadian Asset Management LLC also boosted its stake by 274,666 shares, now holding 689,114 shares worth approximately $2,061,000, a 66.3% rise. Vanguard Capital Management LLC opened a new position with 678,652 shares, valued at $2,035,956. Meanwhile, Nano Cap New Millennium Growth Fund LP significantly increased its holdings by 335,000 shares to 585,000 shares, a 134% increase in its position.
Exagen Inc. Stock Down 47.1%
Shares of XGN traded near $4.45 on Monday. The company's stock has seen active trading from both insiders and institutions recently. XGN's current market conditions are being closely watched by investors and analysts alike.
Insider Buying and Selling at Exagen Inc.
On June 9, 2026, Scott Kahn, along with Frank Stokes and Chas McKhann, each purchased 37,500 shares of XGN. These transactions were not part of a planned trading program. Earlier in the year, on March 12, 2026, John Aballi, President and CEO, bought 100,000 shares at $3.16 per share and an additional 150,000 shares at no cost specified. Jeffrey Black, the Chief Financial Officer, also acquired 75,000 shares at $3.16 per share on the same date.
Analysts Set New Price Targets
On May 12, 2026, BTIG maintained its buy rating on XGN with a price target of $8. Canaccord Genuity also upheld its buy rating with the same target on April 20, 2026. The consensus among analysts remains positive, with a strong buy recommendation and a mean price target reflecting optimism about the company's future prospects.
Bottom Line
Scott Kahn's recent purchase of XGN shares adds to a series of insider buys, suggesting confidence in the company's prospects. Institutional investors are actively adjusting their positions, reflecting varied strategies. Analysts continue to support the stock with favorable ratings and price targets, indicating a positive outlook despite the stock's current trading range.
Related Filing Alerts
Source: Scott Kahn's Form 4 filing on $XGN (Jun 9, 2026). Find the original filing: XGN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts